Leukocyte ImmunoTest™: point-of-care test for monitoring chemotherapy-induced neutropenia

白细胞免疫测试™：用于监测化疗引起的中性粒细胞减少症的护理点测试

• 批准号: 104445
• 金额: $ 8.92万
• 依托单位: OXFORD MEDISTRESS LTD
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2019
• 资助国家: 英国
• 起止时间: 2019 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=104445
• 关键词: Leukocyte; ImmunoTest; point; care; test

"Drug companies are continuing to develop new and improved drugs and medications in the fight against cancer, and more cancer patients are benefiting from these so-called ""chemotherapy"" drugs. However, a key challenge is the risk of unwanted drug side effects which are called adverse drug responses (ADRs). A common ADR that is also quite severe affects the white blood cells of the immune system, reducing the effectiveness of the body to ward off infection (a condition known as ""neutropenia""). Patients with severe neutropenia are more susceptible to bacterial infection and, without prompt medical attention, the condition may become life-threatening.To address this unmet clinical need, Oxford MediStress (OMS) has recently developed the Leukocyte ImmunoTest(tm) (LIT(tm)) for rapidly assessing the function of neutrophils (a type of white blood cell and a key aspect of the immune system). This blood test is rapid (taking only ten minutes), portable, and uses a hand-held point-of-care (POC) electronic device; it uses a tiny pinprick of blood and shows how well your immune system is working. This shows the doctor how well your body is responding to you medication; it shows this quickly and at any point in time. Importantly, the device can eventually be developed for use at home (much like the well-known home diabetes test). Eventually, we will also have a smartphone-enabled app to communicate the results directly to the doctor (but that is not part of this project).Importantly, in order to make it suitable for home-use, some aspects of the device need to be improved. In this project, Oxford MediStress will lead a small team to improve the device by developing a new reagent cartridge that has the necessary chemicals already pre-loaded so that it is easier and quicker to use.As a side benefit, we will also learn whether and how our test can be used to monitor other disease conditions and how doctors in the NHS would likely use this technology to help both the patients (by saving lives) and the healthcare service (by reducing cost and making the provision of excellent healthcare more efficient)."

“制药公司正在继续开发新的和改进的药物来对抗癌症，越来越多的癌症患者正在从这些所谓的“化疗”药物中受益。然而，一个关键的挑战是药物副作用的风险药物不良反应 (ADR) 是一种常见的药物不良反应，它会影响免疫系统的白细胞，降低身体抵御感染的有效性（一种称为“中性粒细胞减少症”的病症）。重症患者中性粒细胞减少症更容易受到细菌感染，如果不及时就医，这种情况可能会危及生命。为了解决这一未满足的临床需求，Oxford MediStress (OMS) 最近开发了白细胞免疫测试 (tm) (LIT(tm))快速评估中性粒细胞（白细胞的一种，是免疫系统的一个关键方面）的功能。这种血液测试快速（只需十分钟），便于携带，并使用手持式护理点。 （POC）电子设备；它使用一点点血液来显示您的免疫系统的运作情况。这向医生显示您的身体对药物的反应如何；它可以在任何时间点快速显示这一点。重要的是，该设备最终可以开发用于家庭使用（就像众所周知的家庭糖尿病测试一样）。最终，我们还将拥有一个支持智能手机的应用程序，可以将结果直接传达给医生（但这不是该项目的一部分）。重要的是，为了使其适合家庭使用，设备的某些方面需要得到改善。在这个项目中，Oxford MediStress 将带领一个小团队通过开发一种新的试剂盒来改进该设备，该试剂盒已预先加载了必要的化学物质，以便更容易、更快速地使用。作为一个附带好处，我们还将了解是否以及如何使用我们的测试来监测其他疾病状况，以及 NHS 的医生如何使用这项技术来帮助患者（通过挽救生命）和医疗服务（通过降低成本并更有效地提供优质医疗保健） ）”。